drugset / Trial / NCT06479759
LM-108 Antibody Combination With Sintilimab for Locally Advanced or Metastatic Non-Small Cell Lung Cancer
Non-randomizedParallel-groupOpen-labelTreatment
Summary
The goal of this clinical trial is to investigate the efficacy, safety and tolerability of LM-108 antibody in combination with sintilimab for patients with locally advanced or metastatic Non-Small Cell Lung Cancer patients.
Timeline
- Start
- 2024-01-12
- Primary completion
- 2025-06-12
- Completion
- 2025-12-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CAFELKIBART | Monoclonal antibody | — | — |
| Subject | Sintilimab | Monoclonal antibody | — | — |